Q-omics provides the consensus-scored ZFHX2 profile across patient tissues and cancer cell-line models. ZFHX2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZFHX2 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ZFHX2 RNA expression shows 20,000 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where ZFHX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFHX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFHX2 survival associations across molecular data types. ZFHX2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFHX2 RNA expression–survival associations across cancer types. High ZFHX2 expression shows unfavorable associations in ACC, LIHC and THYM, but favorable associations in HNSC, PAAD and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZFHX2 RNA expression.
This table summarizes ZFHX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZFHX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFHX2 shows lower tumor expression in KIRC, KICH, LUSC and UCEC and higher tumor expression in LIHC and BRCA. The KIRC box plot shows higher ZFHX2 RNA expression in normal versus tumor tissue (log2 FC = −1.068, t-test p < 0.001).
This table shows molecular features associated with ZFHX2 in patient tissues and cancer cell lines. In patient samples, ZFHX2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFHX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
